Claim OwnershipTalking Precision Medicine
Subscribed: 34Played: 229
Subscribe
© 908529
Description
Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.
49 Episodes
Reverse
Joining us on this episode is Mida Pezeshkian, an old colleague and friend. Mida’s career has spanned from the depths of stem cell science as a student to her current focus on product management in healthcare. We talk about what it really takes to launch products in this space, and how she helps customers bring truly transformational innovations to market.TPM E49 highlights >Episode 49 links:Mida Pezeshkian on LinkedInSTEMA_cgThe Lab
Today on the show, I’m joined by Michael Montalto, vice president of precision medicine at Amgen. Amgen is widely recognized as one of the most successful pharmaceutical companies in translating research and development into approved therapies. A key part of that success comes from their focus on precision medicine, and Mike brings a unique perspective from the forefront of that work.TPM E48 highlights >Episode 48 links:AmgenMichael Montalto on LinkedInGenialis presents a poster at ISMB/ECCB 2025
Joining us on this episode is Tom Neyarapally, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.TPM E47 highlights >Episode 47 links:Archetype TherapeuticsTom Neyarapally on LinkedIn “Exploring a “Patient-First” Path in Drug Discovery”, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten
Stéphane Budel, founding partner at DeciBio, joins the Talking Precision Medicine Podcast to explore the future of the field. He unpacks how liquid biopsy, multi-omics, and AI are opening new doors for personalized care, why the diagnostics business model is holding innovation back, and what it will take to make complex tech usable for clinicians and patients alike.TPM E46 highlights >Episode 46 links:DeciBioStephane Budel on LinkedInDeciBio’s White Paper on AI in Drug Development (with contributions from Rafael Rosengarten)
Today’s guests are Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, and Sudheer Doss, Chief Business Officer at PanCAN. The Pancreatic Cancer Action Network is the leading organization dedicated to advancing progress against pancreatic cancer. It empowers patients and caregivers, drives early detection strategies, and revolutionizes the development of advanced and personalized treatments.TPM E45 highlights >Episode 45 links:Anna Berkenblit on LinkedInSudheer Doss on LinkedInPanCANFor access to data through PanCAN’s SPARK platform, please visit: PanCAN.org/sparkFor more information, contact PanCAN Patient Services with questions about any type of pancreatic cancer – we are here to help.
Today’s guest is Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals.Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader.It has become an iconic name in the field of artificial intelligence for drug discovery.TPM E44 highlights >Episode 44 links:Najat Khan on LinkedInRecursion
What a pleasure to welcome today’s guest, Ryan Fukushima, chief operating officer of TempusAI. Not only has Ryan helped build Tempus brick by brick from the earliest days, he is also CEO of Pathos AI, a biotech company using real world data and AI to develop true precision medicines. I don’t know how he juggles it all, but unless you’ve been hiding out these last few years, Tempus has become a household name in our industry, completing a highly successful IPO last year. But no need to take my word for it, come on in and have a listen!TPM E43 highlights >Episode 43 links:Ryan Fukushima on LinkedInTempus AIPathosTempus announces multi-year collaboration with Genialis
Today my guest is Joydeep Goswami, newly appointed President and CEO of the storied biotechnology company LGC. Joydeep is also a strategy advisor to Genialis. Join us as we discuss his remarkable career and lessons learned at each step of the way.
Come on in and have a listen.
Episode 42 links:
TPM E42 for highlights and links from this episode >
Tempus Announces a Collaboration With Genialis
Genialis’ Upcoming Events
This episode features a conversation with Shweta Maniar, who leads the Healthcare and Life Science effort at Google cloud. In just a few short years, artificial intelligence has gone from the stuff of hype and fairy tale to powerful and ubiquitous tools for all aspects of R&D and healthcare delivery. Google has been central to this sea change. I discuss with Shweta how her organization helps make these advanced capabilities available to the masses, and so much more. Join us!
Episode 41 links:
TPM E41 for highlights and links from this episode >
Genialis™ Supermodel
Happy Holidays
Genialis' Upcoming Events
Genialis on LinkedIn
Our guest this episode is Charles Fisher, co-founder and currently Chief Scientific Officer of Unlearn.AI. Unlearn has been a leader in the advancement of Digital Twins as a tool to drastically improve the efficiency of clinical trials. Not only a visionary scientist and trailblazing entrepreneur, Charles is fearless with his hot takes. So sit back and enjoy this free wheeling conversation!
Episode 40 links:
TPM E40 for highlights and links from this episode >
Potential of the Xerna™ TME Panel as a Predictive Biomarker (SITC 2024 Poster)
Genialis’ Upcoming Events
Genialis on LinkedIn
What a genuine pleasure to sit with Thierry Bernard, CEO of Qiagen. As I told Thierry, Qiagen is a truly iconic brand for anyone who came up through molecular biology laboratories in the past 30 years. Their products were ubiquitous, and crucial, to the success of our research. In this conversation, Thierry talks about his global vision for precision medicine, and his mantra that we leave no patient behind.
Episode 39 links:
TPM E39 for highlights and links from this episode >
Genialis™ krasID Poster at 6th Annual RAS-Targeted Drug Development Summit 2024
Genialis’ Upcoming Events
Genialis on LinkedIn
What a pleasure to sit down with my long time colleague and friend, Art Krieg, to discuss his latest venture, Zola Therapeutics, and his adventures in the great outdoors. Art has launched and exited a number of innovative biotechs, each time delving deeper into mechanisms by which we can harness the immune system for therapeutic purposes. Join us as we discuss how — despite a well earned retirement — the siren song that led to Zola was strong enough to get Art back in the game.
Episode 38 links:
TPM E38 for highlights and links from this episode >
Genialis’ Upcoming Events
Genialis™ krasID
In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem.
Episode 37 links:
TPM E37 for highlights and links from this episode >
Genialis’ Upcoming Events
Genialis™ krasID
This episode features two guests, Jennifer Goldsack and Yashoda Sharma, of the Digital Medicine Society, or DiMe. We’re going to get into the nitty gritty of healthcare disparities in terms of access and outcomes, and how digital solutions are a big part of the overall solution.
Episode 36 links:
TPM E36 for highlights and links from this episode >
Genialis’ Upcoming Events
Genialis™ krasID
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Episode 35 links:
Visit TPM E35 for highlights and links from this episode >
Learn more about Genialis™ krasID >
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients >
Today we turn the mic around, as our guest Adam Stasio hosts an excellent podcast of his own. Adam’s day job, however, is running SciMed, a boutique life sciences software development company. Adam and Genialis CEO Rafael Rosengarten discuss the state of scientific software, the importance of agility and communication, and approaches to building a lasting company culture.
Visit TPM E34 for highlights and links from this episode.
Our guest today is Dr. Ashley Zehnder, co-founder and CEO of Fauna Bio. Fauna is a revolutionary young biotech company using comparative genomics of an array of non-traditional mammalian models to discover new therapeutic opportunities for people. What do ground squirrels have to do with treating battlefield trauma? Only one way to find out …
Visit TPM E33 for highlights and links from this episode.
In this episode, Genialis CEO Rafael Rosengarten sits down with Ajay Gopal, CEO and founder of Rx Studio. Rx Studio is a technology company using data science to tackle a major limitation to personalized medicine: drug dosing.
Visit TPM E32 for highlights and links from this episode.
In this episode, Genialis CEO Rafael Rosengarten speaks with BCG management consultant and healthcare innovation expert Amy MacDougall. They discuss emerging trends in healthcare, the role of AI, ethics and more, as well as BCG’s recently released 50 Most Innovative Companies List.
Visit TPM E31 for highlights and links from this episode.
This episode, Genialis’ thirtieth, is a bit different from the previous ones. CEO Rafael Rosengarten has not one, not two, but three guests, including the entire leadership team at Genialis. The gang discusses Genialis’ twin quests to build a great place to work and a business that makes a positive impact on the world.
Visit TPM E30 for highlights and links from this episode.
Comments
Download from Google Play
Download from App Store
United States